Nav: Home

American College of Physicians releases clinical practice guidelines for acute gout

October 31, 2016

Philadelphia, Nov.1, 2016 -- Physicians should use corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout, the American College of Physicians (ACP) recommends in a new evidence-based clinical practice guideline for the management of the painful form of arthritis published today in Annals of Internal Medicine. ACP's guideline for diagnosing gout was published in the same issue.

"Physicians should consider using corticosteroids first in patients without contraindications because they are one of the most effective anti-inflammatory medications available and they are as effective as NSAIDs for managing acute gout but have fewer adverse effects," said Nitin S. Damle, MD, MS, MACP, president, ACP. "Although a generic formulation of colchicine is now available, it is more expensive than NSAIDs or corticosteroids. This is an important consideration for patients, especially as prescription drug prices continue to increase."

If colchicine is used to treat acute gout, ACP recommends that physicians use a low dose. The evidence showed that lower doses are as effective as higher doses at reducing pain and are associated with fewer gastrointestinal adverse effects. Possible adverse effects associated with colchicine include diarrhea and other gastrointestinal symptoms.

ACP found insufficient evidence to determine the effectiveness of dietary changes on symptomatic outcomes for the treatment of gout. Low-quality evidence from one study showed that gout-specific counseling about dietary changes -- such as reducing red meat, shellfish, yeast-rich foods, and increasing low-fat dairy, vegetables, and cherries -- is not more effective than general dietary counseling -- such as promoting weight loss and reducing alcohol intake -- for reducing serum urate levels in gout patients.

ACP recommends against initiating long-term uric acid-lowering therapy in most patients after a first gout attack or in patients with infrequent attacks.

While the evidence supports the benefits of using uric acid-lowering therapy for shorter duration to reduce gout flares, the benefits of long term usage for 12 or more months in patients with a single or infrequent gout attacks have not been studied. In most patients, it is not clearly necessary, based on the evidence, to start uric acid-lowering therapy in cases where the individuals would have no or infrequent recurrences, ACP states in the guideline.

In cases of recurrent gout, ACP recommends that physicians and patients discuss the benefits, harms, costs, and individual preferences before initiating uric acid-lowering therapy. Patients who decide not to initiate uric acid-lowering therapy can revisit their decision if and when they have multiple recurrent attacks of gout.

ACP called for the need for comparative effectiveness studies to evaluate the incremental benefits and harms of a treat-to-target strategy over a treat-to-avoid-symptoms strategy.

For diagnosing gout, ACP recommends that physicians use synovial fluid analysis when clinical judgement indicates that diagnostic testing is necessary in patients with possible gout.

"While joint aspiration with synovial fluid analysis for uric acid crystal analysis is the reference standard for diagnosing gout, most patients are seen initially by their primary care physician or an emergency room physician where synovial fluid analysis is less frequently and less easily performed," Dr. Damle said. "In certain situations, physicians should use clinical judgement so that patients can begin treatment if gout is suspected."

Misdiagnosis or delayed diagnosis of gout can result in unnecessary surgery, hospitalization, delays in adequate treatment such as antibiotics for septic joints, and unnecessarily prescribing long-term treatment to patients.
ACP's Guideline Development Process

ACP's guidelines for managing and diagnosing acute gout are based on two systematic evidences review sponsored by the Agency for Healthcare Research and Quality's (AHRQ) and conducted by RAND's Southern California Evidence-based Practice Center.

ACP's clinical practice guidelines are developed through a rigorous process based on an extensive review of the highest quality evidence available, including randomized control trials and data from observational studies. ACP also identifies gaps in evidence and direction for future research through its guidelines development process.

About Gout

Gout is one of the most common forms of inflammatory arthritis. It is caused by excess uric acid crystals accumulating in joint fluid, cartilage, bones, tendons, and other sites. Patients experience joint swelling and pain during gout attacks. Risk factors for gout include being male, being overweight, excess alcohol intake, diuretic use, a diet rich in meat and shellfish, food or drinks high in fructose, and poor kidney function. An estimated $1 billion is spent on ambulatory care for gout, largely on treatments and prescription medications.

About the American College of Physicians

The American College of Physicians is the largest medical specialty organization in the United States. ACP members include 148,000 internal medicine physicians (internists), related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness.

American College of Physicians

Related Corticosteroids Articles:

New medicine shows potential to reduce oral steroid use in severe asthma patients
The results of the trial, published this week in the New England Journal of Medicine, demonstrate that patients treated with a potential new medicine and antibody, called benralizumab, were more than four times likely to reduce their usage of oral corticosteroids than those taking a placebo.
Got hives? Hold the steroids
Despite standard use for the itching associated with urticaria (commonly known as hives), prednisone (a steroid) offered no additional relief to emergency patients suffering from hives than a placebo did, according to a randomized, placebo-controlled, double-blind, parallel-group study published online yesterday in Annals of Emergency Medicine ('Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial').
Inhaled steroids may increase pneumonia risk in people with asthma
Use of inhaled corticosteroids was linked with an increased risk of pneumonia in a study of individuals with asthma.
Inhaled corticosteroids may raise women's risk of the metabolic syndrome
Use of inhaled corticosteroids in women is associated with a higher body mass index (BMI) and an increased prevalence of the metabolic syndrome, which is a cluster of risk factors for type 2 diabetes and heart disease, researchers have found.
Very premature babies benefit most from corticosteroids before birth
Giving corticosteroid drugs to mothers at risk of preterm delivery -- from as early as 23 weeks of pregnancy -- is associated with a lower rate of death and serious illness for their babies, finds a study published by The BMJ today.
Antibiotics not effective for clinically infected eczema in children
There is no meaningful benefit from the use of either oral or topical antibiotics for milder clinically infected eczema in children.
A breath of fresh air for severe asthma research
New research led by a team of investigators at Brigham and Women's Hospital points to immunological differences in responses to steroids in patients with severe asthma, suggesting why corticosteroids may paradoxically perpetuate inflammation in severe asthma.
Steroid use linked to worse outcomes in Lyme disease-associated facial paralysis
Researchers from Massachusetts Eye and Ear/Harvard Medical School have found that patients who were prescribed corticosteroids as part of treatment for Lyme disease-associated facial paralysis had worse long-term outcomes of regaining facial function than those who were prescribed antibiotic therapy alone.
Updated Cochrane Review: Corticosteroids for managing tuberculous meningitis
The Cochrane Infectious Diseases Group have carried out a review update to evaluate the effects of corticosteroids being used alongside anti-tuberculosis medication to treat people suffering from tuberculous meningitis.
SMFM releases statement on use of antenatal corticosteroids in late preterm birth period
The Society for Maternal-Fetal Medicine released a statement on the use of antenatal corticosteroids during the late preterm birth period for women at risk of preterm birth.

Related Corticosteroids Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".